

1 **Risk of SARS-CoV-2 testing, PCR-confirmed infections and COVID-19--related hospital**  
2 **admissions in children and young people: birth cohort study**

3 Pia Hardelid,<sup>1†</sup> Graziella Favarato,<sup>1</sup> Linda Wijlaars,<sup>1</sup> Lynda Fenton,<sup>2</sup> Jim McMenamin,<sup>3</sup> Tom  
4 Clemens,<sup>4</sup> Chris Dibben,<sup>4</sup> Ai Milojevic,<sup>5</sup> Alison Macfarlane,<sup>6</sup> Jonathon Taylor,<sup>7</sup> Steven  
5 Cunningham,<sup>8\*</sup> Rachael Wood.<sup>9\*</sup>

6 <sup>1</sup>Population, Policy and Practice Research and Teaching Department, University College  
7 London Great Ormond Street Institute of Child Health, London, UK

8 <sup>2</sup>Clinical and Public Health Intelligence Team, Public Health Scotland, Edinburgh, UK

9 <sup>3</sup>Public Health Scotland, Respiratory Infection Team, Glasgow, UK

10 <sup>4</sup>School of Geosciences, The University of Edinburgh, Edinburgh, UK

11 <sup>5</sup>Department of Public Health, Environments and Society, London School of Hygiene &  
12 Tropical Medicine, London, UK

13 <sup>6</sup>Centre for Maternal and Child Health Research, City, University of London, London, UK

14 <sup>7</sup>Faculty of Built Environment, Tampere University, Tampere, Finland

15 <sup>8</sup>Centre for Inflammation Research, University of Edinburgh, Edinburgh, UK

16 <sup>2,9</sup>Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK

17 **\*\*Joint last authors**

18 <sup>†</sup>Corresponding author. Address for correspondence: <sup>1</sup>Population, Policy and Practice  
19 Research and Teaching Department, University College London Institute of Child Health, 30  
20 Guilford Street, London WC1N 1EH, UK. [p.hardelid@ucl.ac.uk](mailto:p.hardelid@ucl.ac.uk)

21

22

23

24 **Abstract**

25

26 **Background**

27 There have been no population-based studies of SARS-CoV-2 testing, PCR-confirmed  
28 infections and COVID-19-related hospital admissions across the full paediatric age range.  
29 We examine the epidemiology of SARS-CoV-2 in children and young people (CYP) aged  
30 <23 years.

31

32 **Methods**

33 We used a birth cohort of all children born in Scotland since 1997, constructed via linkage  
34 between vital statistics, hospital records and SARS-CoV-2 surveillance data. We calculated  
35 risks of tests and PCR-confirmed infections per 1000 CYP-years between August and  
36 December 2020, and COVID-19-related hospital admissions per 100,000 CYP-years  
37 between February and December 2020. We used Poisson and Cox proportional hazards  
38 regression models to determine risk factors.

39

40 **Results**

41 Among the 1226855 CYP in the cohort, there were 378402 tests, 19005 PCR confirmed  
42 infections and 346 admissions, corresponding to rates of 770.8/1000 (95% confidence  
43 interval 768.4-773.3), 179.4 (176.9-182.0) and 29.4/100,000 (26.3-32.8) CYP-years  
44 respectively. Infants had the highest COVID-19-related admission rates. Chronic conditions,  
45 particularly multiple types of conditions, was strongly associated with COVID-19-related  
46 admissions across all ages. The hazard ratio for >1 chronic condition type was 12.2 (7.9-  
47 18.82) compared to children with no chronic conditions. 89% of admitted children had no  
48 chronic conditions recorded.

49

50 **Conclusions**

51 Infants, and CYP with chronic conditions are at highest risk of admission with COVID-19,  
52 however the majority of admitted CYP have no chronic conditions. These results provide  
53 evidence to support risk/benefit analyses for paediatric COVID-19 vaccination programmes.  
54 Studies examining whether maternal vaccine during pregnancy prevents COVID-19  
55 admissions in infants are urgently needed.

56

57 **Funding**

58 UK Research and Innovation-Medical Research Council

59

## 60 **Background**

61 Children are much less likely to experience hospital admission and mortality related to  
62 severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection than adults.<sup>1</sup> In  
63 Europe in 2020, 1.7% of COVID-19-related hospital admissions were in children <19 years  
64 of age.<sup>2</sup>

65 Whilst early reports during the spring and summer of 2020 indicated less than 5% of SARS-  
66 CoV-2 positive cases in the United States,<sup>3</sup> China<sup>4</sup> and Spain<sup>5</sup> were in children, the  
67 epidemiology has changed over time and place, particularly in association with vaccination  
68 policy and access, with children under 10 years of age being the dominant population  
69 infected in the latter part of 2021 in the UK..<sup>6</sup>

70 Over the course of the pandemic our understanding of how SARS-CoV-2 infection affects  
71 children has also improved. Children who experience more severe symptoms of SARS-CoV-  
72 2 may present with acute infection symptoms such as fever, cough, shortness of breath,  
73 nausea/vomiting, or upper respiratory symptoms.<sup>7-9</sup> Children may also present with an acute  
74 inflammatory syndrome, paediatric inflammatory syndrome temporally associated with  
75 SARS-CoV-2 (PIMS-TS; also referred to as multisystem inflammatory syndrome related to  
76 COVID - MIS-C), several weeks after initial infection.<sup>10-12</sup> Children aged <2 years old appear  
77 to be over-represented among children admitted to hospital with acute symptoms of SARS-  
78 CoV-2 infection, whereas children aged 10 years or older account for the largest proportion  
79 of admitted PIMS-TS cases.<sup>8 13</sup>

80 Two preprints indicate that among children admitted to hospital with SARS-CoV-2 or PIMS-  
81 TS, those with specific chronic respiratory, neurological, gastrointestinal or cardiovascular  
82 conditions, and particularly children with multiple comorbidities, were at increased risk of  
83 Paediatric Intensive Care Unit (PICU) admission or death. Infants and teenagers appeared  
84 to have higher odds of these severe outcomes compared to children aged 1-4 years old.<sup>14 15</sup>  
85 A lower reported risk of severe disease and, until 2021, relatively lower rates of infection in  
86 children have supported a narrative that the benefits and risks (primarily of myocarditis  
87 following second dose mRNA vaccines in young men<sup>16 17</sup>) of vaccinations in children are  
88 finely balanced.

89 Most studies of paediatric SARS-CoV-2 infection have been case series of infected or  
90 hospitalised children, making calculations of population-based risks of confirmed infections  
91 and associated admissions among different groups of children, including children with  
92 chronic conditions, impossible. A recent study presented population-based risks of COVID-

93 19-related admission for children with asthma, indicating an increased risk that supports  
94 vaccine strategies targeted to this group.<sup>18</sup> Our aim was to provide population based  
95 estimates of risk of SARS-CoV-2 testing, PCR confirmed infections and COVID-19 related  
96 admissions in children and young people (CYP) based on age, presence of multiple chronic  
97 conditions, and socioeconomic status, that could support vaccination and other policy  
98 recommendations across the whole paediatric population.

## 99 **Methods**

### 100 *Data sources*

101 We used a national birth cohort of all children and young people (CYP) born in Scotland from  
102 1997 onwards, developed from administrative health datasets linked to public health  
103 surveillance data on SARS-CoV-2 test results, originally constructed for the PICNIC study.<sup>19</sup>  
104 CYP born in 1997 onwards were included. Birth registrations comprised the cohort spine,  
105 and CYP are linked over time and between databases using the Community Health Index  
106 (CHI) number, a unique personal identifier recorded at all interactions with the Scottish  
107 National Health Service (NHS). Table 1 summarises the databases and variables used in  
108 this study.

109

110 **Table 1. Datasets and variables from the national Scottish birth cohort used in the**  
 111 **study**

<b>Dataset</b>	<b>Dataset details</b>	<b>Variables used</b>
National Records for Scotland (NRS) birth registrations	Vital registration data on all children born in Scotland and their parents, collected via registry offices	Week and year of birth; Baby Sex; Socio-economic position (parents' occupation at birth).
Scottish Morbidity Record (SMR)-01	Contains data on post-neonatal admissions and day cases to all NHS hospitals in Scotland	Admission and discharges dates; Primary and secondary diagnoses during admission; Type of hospital admission; Admission and discharge data from Intensive Care Unit (ICU).
SMR-02 (maternity records)	Contains data on all maternity admissions (including deliveries) in Scotland	Estimated gestational age; birth weight; number of older siblings (parity).
COVID-19 Tests	Contains data on all PCR- and antigen tests for SARS-Cov-2 with results and dates	Date of testing; Type of test; Result.
National Records for Scotland (NRS) death registrations	Vital registration data on children who died in Scotland	Date of death; Cause of death.
Scottish Birth Records (SBR)	Contains data on all children born in NHS hospitals, with data on neonatal admissions in and after April 2003	Diagnoses recorded at or shortly after birth ; Primary and secondary diagnoses at birth admission.
CHI register	Contains data on migration in/out Scotland	Migration outside Scotland.
Child Health Surveillance Programme-School	Contains data school health visits	Height and weight at age 5

112

113

114 *Study population and follow-up*

115 We included CYP born in Scotland from 1<sup>st</sup> April 1997 to 31<sup>st</sup> December 2020. Children born  
116 at less than 24 completed weeks' gestation or with a birthweight <500 grammes were  
117 excluded to ensure stillbirths were not inadvertently included.<sup>20</sup> CYP whose mothers were  
118 not resident in Scotland at the time of delivery, and CYP who migrated out of Scotland  
119 before 1<sup>st</sup> February 2020 were also excluded. For analyses of SARS-CoV-2 tests and  
120 positive test results (from now on referred to PCR-confirmed infections), CYP were followed  
121 from birth or the 1<sup>st</sup> August 2020 (whichever occurred last), until death, migration from  
122 Scotland, or their 23<sup>rd</sup> birthday, whichever occurred first. 1<sup>st</sup> August 2020 was chosen as the  
123 follow-up start date for analyses of tests and PCR-confirmed infections since this is when  
124 testing for SARS-CoV-2 became commonly available in the community (rather than solely in  
125 hospitals) for children of all ages.<sup>21</sup> For calculation and analyses of rates of COVID-19-  
126 related admissions, we used the follow-up start date as the 1<sup>st</sup> February 2020. This allowed  
127 us to include all COVID-19-related hospital admissions since PCR testing for SARS-CoV-2  
128 was available for suspected cases in hospital from January 2020.

129 *Outcomes*

130 Our primary outcomes were rates of a) SARS-CoV-2 PCR tests (positive or negative); b)  
131 PCR-confirmed SARS-CoV-2 infections; c) COVID19-related hospital admissions. We also  
132 considered as secondary outcomes d) PIMS-TS admissions and e) COVID19-related  
133 intensive care unit (ICU) stays.

134 For a), we included all SARS-CoV-2 PCR tests recorded between 1<sup>st</sup> August 2020 and 31<sup>st</sup>  
135 December 2020 in the COVID19 Tests Dataset. The samples were collected in hospitals,  
136 primary care, via national testing centres, or self-collection via home test kits. We did not  
137 include antigen (lateral flow device) test results, as they were not comprehensively  
138 represented in the COVID19 Tests dataset during 2020 (only 5% of test results in the cohort  
139 during the study period were from lateral flow devices). We defined as duplicate tests  
140 multiple tests taken on the same day, in the same CYP, with the same result, irrespective of  
141 whether they were taken at different locations. All duplicate tests, whether positive or  
142 negative, were excluded when calculating testing rates. For b), a PCR-confirmed SARS-  
143 CoV-2 infection was defined as the first record of a positive SARS-CoV-2 PCR test result  
144 (the index positive test) recorded in the COVID19 Tests dataset between 1<sup>st</sup> August 2020 and  
145 31<sup>st</sup> December 2020. Public Health Scotland recommends excluding all repeat positive tests  
146 within 90 days of the index positive sample date, and less than 5 CYP had multiple positive  
147 results beyond this time period. Therefore, only the first positive SARS-CoV-2 PCR test

148 result for each child was included when calculating rates of PCR-confirmed SARS-CoV-2  
149 infections, and identifying COVID-19-related hospital admissions.

150 We included all COVID-19-related hospital admissions (outcome c) between 1<sup>st</sup> February  
151 and 31<sup>st</sup> December 2020. To define COVID-19 related hospital admissions, we first linked  
152 episodes in the hospital admission dataset (Scottish Morbidity Record-01; Table 1) into  
153 admissions by assuming that episodes where the difference between the admission date  
154 and previous discharge date was  $\leq 1$  day<sup>22</sup> indicated the same admission. Second, we  
155 identified COVID-19 related admissions where: (i) an individual had tested positive for  
156 SARS-CoV-2 up to 14 days prior to hospital admission, on the day of admission, or in  
157 between the hospital admission and discharge date, and/or (ii) an International Classification  
158 of Diseases-version 10 (ICD-10) diagnostic code for COVID-19 (U07.1 – U07.2) had been  
159 recorded during an admission as a primary or secondary diagnosis.

160 Since the ICD-10 code for PIMS-TS (U07.5) was introduced at the end of the follow-up  
161 period, we used other ICD-10 codes indicating systemic inflammatory response syndrome of  
162 infectious origin without organ failure (R65X), cardiogenic shock (R57X) or other specified  
163 systemic involvement of connective tissue (M35.8), suggestive of PIMS-TS recorded during  
164 an admission which had a positive SARS-CoV-2 PCR test within 28 day prior to the  
165 admission date.

166 A COVID-19-related intensive care unit (ICU) stay (outcome e) was defined where a child  
167 had an SMR-01 episode with 'significant facility' recorded with a positive SARS-CoV-2 PCR  
168 test to 21 days prior to the start of, or during, the ICU stay. ICU episodes where the  
169 difference between the ICU admission date and previous ICU discharge date was  $\leq 1$  day  
170 were assumed to indicate the same ICU stay.

#### 171 *Risk factors*

172 We examined four risk key factors for outcomes a-c): age group, sex, family socio-economic  
173 position (SEP) and history of chronic conditions. Age group was defined on 1<sup>st</sup> February  
174 2020 as the following five categories: <1 year (this also includes children born during 2020),  
175 1-4 years, 5-11 years, 12-17 years and 18-22 years. We chose these age groups to reflect  
176 likely mixing patterns based on age (i.e. prior to formal childcare, nursery/preschool, primary  
177 school, secondary school, and higher/further education or work). Sex was recorded on the  
178 birth record. Family SEP was defined using parents' (father's, or mother's if the birth was not  
179 jointly registered) occupation recorded on birth registration. This was coded using the UK  
180 National Statistics Socio-economic Classification (NS-SEC).<sup>23</sup> We collapsed the NS-SEC

181 classes into three groups: high SEP (managerial and professional occupations), middle SEP  
182 (intermediate occupations) and low SEP (routine and manual occupations). We identified  
183 history of chronic conditions by examining ICD-10 diagnostic codes recorded in SMR-01 in  
184 the previous five years. For children aged less than five years old at the start February 2020  
185 or born during 2020, we used all available SMR-01 data and any diagnoses recorded on  
186 Scottish Birth Records. The code list for identifying chronic conditions was developed by  
187 Hardelid et al;<sup>24</sup> and classifies chronic conditions into 8 types depending on body system:  
188 developmental/mental health, blood/cancer, chronic infections, respiratory,  
189 metabolic/gastrointestinal/endocrine/genitourinary, musculoskeletal/skin  
190 neurological/sensory, and cardiac conditions. We grouped the history of chronic conditions  
191 as none, one type of condition, and more than type of chronic condition.

192 We further explored whether gestational age and the number of older siblings affected  
193 outcomes b) and c) in children aged <5 years, and BMI in CYP aged 5-17, after adjusting for  
194 the four key risk factors. Gestational age was coded into a binary variable: preterm (<37  
195 weeks) and term/late term ( $\geq 37$  weeks). Number of older siblings (indicated by parity  
196 recorded on maternity records) was grouped into a three-category variable: no older siblings,  
197 one older sibling and two or more older siblings. BMI was derived from the Child Health  
198 Surveillance Programme -School dataset, which includes height and weight measurements  
199 for children starting their first (reception) year at primary school (at age 5 years), categorised  
200 using the British 1990 growth reference standards<sup>25</sup> as underweight (<5<sup>th</sup> percentile), healthy  
201 weight (5<sup>th</sup> to <85<sup>th</sup> percentile) and overweight/obese ( $\geq 85^{\text{th}}$  percentile).

## 202 *Statistical analyses*

203 We calculated rates of outcomes a) and b) per 1,000 CYP years and outcome c) per  
204 100,000 CYP-years with 95% confidence intervals, according to each of the risk factors. We  
205 estimated the median length of stay with interquartile ranges (IQRs) for COVID-19 related  
206 hospital admissions.

207 We examined the association between risk factors and testing rates using Poisson  
208 regression models with robust standard errors to account for multiple tests per child. To  
209 examine the association between risk factors and PCR-confirmed SARS-CoV-2 infection,  
210 and COVID19-related admission risk we used Cox proportional hazards regression models.  
211 Where a child had multiple COVID-19-related admissions, only the first was included in the  
212 Cox proportional hazards models. For each primary outcome, we first fitted an overall model  
213 including all ages. We included age group, sex, SEP and history of chronic conditions a  
214 priori as risk factors in the main model. We tested for interaction with age group and each of



215 the other main risk factors using the Wald test. Two-sided  $p$ -values  $<0.05$  were considered  
216 statistically significant.

217 Based on these results, we then fitted models for each primary outcome stratified by age  
218 group if a statistically significant interaction with age was identified for any of the other  
219 variables or if we identified non-proportional hazards. In further analyses for ages  $<5$  years  
220 old we included parity and gestational age as additional risk factors in the models; and for  
221 ages 5-17 years we included BMI category. We tested the proportional hazards assumption  
222 of the Cox model by inspecting plots of Schoenfeld residuals<sup>26</sup> and survival curves according  
223 to each main risk factors.

224 As there was only a small number of events for our secondary outcomes, we did not carry  
225 out detailed statistical analyses. We report the number of cases, median length of stay and  
226 age (with IQRs) for these outcomes.

227 All analyses were based on complete cases, as only a small number of CYP and missing  
228 values for any of the main variables. All statistical analyses were performed using Stata  
229 16.0.


### 230 *Sensitivity analyses*

231 We repeated the analyses for outcome c) using a more specific definition of a COVID-19-  
232 related admission restricted to emergency admissions with U07.1 or U07.2<sup>27</sup> as the primary  
233 diagnosis.

## 234 **Results**

235 This study included 1,226,855 CYP (Figure 1). Baseline characteristics of the participants  
236 are presented in Table 2. The median age on February 2020 was 11 years (IQR 5-17), and  
237 5.4% of the cohort (66,974/1,226,855 CYP) had at least one chronic condition recorded in  
238 their hospital or birth record in the previous five years.

239



240

241 **Figure 1** Flow chart describing creation of the final cohort

242

243

244 **TABLE 2 Cohort baseline characteristics (n=1,226,855)**

	Number	%
Sex		
Male	628,410	51.2
Female	598,445	48.8
<i>missing</i>	0	0
Age (years)*		
Median 10.8 (IQR 5-17) yr		
<1 yr	92,539	7.5
1-4 yr	206,677	16.9
5-11 yr	326,455	26.6
12-17 yr	358,195	29.2
18-22 yr	242,989	19.8
<i>Missing</i>	0	0
Socio economic position**		
High	136,938	11.2
Middle	582,342	47.5
Low	507,563	41.4
<i>Missing</i>	12	0
Chronic conditions***		
None	1,159,878	94.5
One	59,972	4.9
More than one type	7,005	0.6
Gestational age (weeks) (aged* <5yr, n=292,289)		
Pre-term (<37 weeks)	23,825	8.0
Normal/Post-term (≥37 weeks)	268,464	89.7
<i>Missing</i>	6,927	2.3
Number of older siblings (aged* <5yr, n=289,800)		
None	124,289	41.5
One	102,944	34.4
Two or more	62,567	20.9
<i>Missing</i>	9,416	3.2
BMI *** (aged* 5-17, n=550,874)		
Underweight	8,930	1.30
Normal	421,182	60.2
Overweight/Obese	120,762	17.6
<i>missing</i>	142,776	20.9

\* As on 1<sup>st</sup> February 2020; aged<1yr includes those born between 1 February 2020 and 31 December 2020. \*\* From UK National Statistics Socio-economic Classification (NS-SEC): SEP (managerial and professional occupations), middle SEP (intermediate occupations), low SEP (routine and manual occupations). \*\*\*Includes any chronic conditions recorded in the hospital records in the previous five years. \*\*\*As recorded in the Child Health Surveillance Programme-School at aged 5 and standardised according to the British 1990 growth reference standards (Cole 1998): underweight (<5<sup>th</sup> percentile), normal weight (5<sup>th</sup> to <85<sup>th</sup> percentile), overweight/obese (≥85<sup>th</sup> percentile).

245


246 *SARS-CoV-2 testing*

247 Between 1<sup>st</sup> August (week 31) to 31<sup>st</sup> December 2020 (week 52) we identified 378,402 PCR  
248 tests linked to 256,741 CYP; hence 20.9% of CYP in the cohort had at least one test. Figure  
249 2 shows the weekly number of PCR tests by age group. The majority of CYP had been  
250 tested only once (200,288; 78.0%); 40,188 (15.7%) had been tested twice and 16,265  
251 (6.3%) more than twice.

252 The crude testing rate was 770.8 (95%CI 768.4-773.3) per 1,000 CYP-years. Testing rates  
253 varied by age group and chronic conditions: children aged 1-4 years, young adults (age 18-  
254 22 years), and those with more than one chronic condition recorded had the highest testing  
255 rates (Appendix Table 1 & 2). Children aged <5 years born preterm were also more likely to  
256 be tested compared to children born at term (Appendix Table 3).

257 Models that mutually adjusted for all four main predictors suggested increasing age (and  
258 particularly an age of 18-22 years) and a history of chronic conditions were strongly  
259 associated with being tested (Table 3). As there was a statistically significant interaction term  
260 between age group and each of the other risk factors, we conducted age group-stratified  
261 analyses (Table 4). A history of chronic conditions was strongly associated with higher  
262 testing rates, with the size of the effect being the largest among infants

263



264  
265

266 **Figure 2** Weekly number of tests (white bars) and positive results (red bars) stratified by age  
267 group (weeks 31-52, 2020)

268

269 .

270 **Table 3 Results of models adjusted for age group, sex, socio-economic position and history of chronic conditions**

	Testing*		PCR confirmed infection**		Admission***	
	Adj IIR	95%CI	Adj HR	95%CI	Adj HR	95%CI
<b>AGE GROUP</b>						
<1year	1	-	1	-	1	-
1-4 years	1.22	1.20, 1.24	0.76	0.68, 0.84	0.13	0.09, 0.19
5-11 years	1.07	1.05, 1.09	1.31	1.19, 1.44	0.11	0.08, 0.15
12-17 years	1.23	1.20, 1.25	3.12	2.85, 3.42	0.13	0.10, 0.19
18-22 years	2.04	2.00, 2.08	4.08	3.73, 4.47	0.29	0.22, 0.40
<b>SEX</b>						
Male	1	-	1	-	1	-
Female	1.17	1.16, 1.17	1.05	1.02, 1.08	1.14	0.91, 1.42
<b>Socio-economic position (SEP)</b>						
High	1.03	1.01, 1.04	1.19	1.13, 1.24	0.57	0.36, 0.89
Middle	1.03	1.02, 1.04	1.12	1.09, 1.16	0.82	0.65, 1.03
Low	1	-	1	-	1	-
<b>CHRONIC CONDITIONS</b>						
None	1	-	1	-	1	-
One	1.28	1.27, 1.30	0.79	0.75, 0.85	2.79	1.98, 3.94
More than one	1.63	1.56, 1.70	0.570	0.58, 0.84	13.09	8.46, 20.27

271 Footnotes:

272 \* Wald test for interaction: age and sex  $p < 0.0001$ ; age and NS-SEC  $p < 0.0001$ ; age and chronic conditions  $p < 0.0001$ ;

273 \*\*interaction: age and sex  $p < 0.0001$ , age and SEP  $p < 0.0001$ , age and chronic conditions  $p = 0.0004$ ; global test to check proportionality assumption  
 274  $p < 0.0001$  (for age, SEP, chronic conditions).

275 \*\*\* interaction: age and sex  $p = 0.045$ , age and NS-SEC  $p = 0.94$ , age and chronic conditions  $p = 0.26$ ; global test to check proportionality assumption  $p$   
 276  $0.0009$  (for age, chronic condition)

277

278

279 **Table 4 Incidence Risk Ratios of being tested by age group mutually adjusted for sex, socio-economic position and**  
 280 **history of chronic conditions**

	Age <1 year		Age 1-4 years		Age 5-11 years		Age 12-17 years		Age 18-22years	
	N		N		N		N		N	
Number of CYP in model	98333		216,048		397751		326249		317625	
N events	9509		59176		92007		79771		137939	
	Adj IIR	95%CI	Adj IIR	95%CI	Adj IIR	95%CI	Adj IIR	95%CI	Adj IIR	95%CI
<b>SEX</b>										
Male	1	-	1	-	1	-	1	-	1	-
Female	0.88	0.85, 0.91	0.90	0.89, 0.92	0.90	0.89, 0.91	1.20	1.18, 1.22	1.61	1.58, 1.63
<b>Socio economic position</b>										
High	1.59	1.52, 1.67	1.32	1.28, 1.35	0.96	0.94, 0.99	0.90	0.88, 0.93	0.93	0.91, 0.96
Middle	1.23	1.18, 1.27	1.11	1.09, 1.13	1.01	0.99, 1.02	0.99	0.97, 1.01	1.01	0.99, 1.03
Low	1	-	1	-	1	-	1	-	1	-
<b>CHRONIC CONDITIONS</b>										
None	1	-	1	-	1	-	1	-	1	-
One	1.97	1.81, 2.15	1.30	1.25, 1.34	1.39	1.35, 1.43	1.37	1.32, 1.42	1.11	1.08, 1.13
More than one	3.53	3.20, 3.89	1.92	1.75, 2.10	2.13	1.95, 2.33	1.63	1.47, 1.80	1.12	1.05, 1.20

281

282

283

284 *PCR-confirmed infections*

285 Among the 378,402 PCR tests identified in the cohort, 20,003 (5.3%) were positive and  
286 7,275 (1.9%) were void. Excluding multiple positive tests per CYP, this corresponds to  
287 19,005 PCR confirmed index infections in 7.4% (19,005/ 256,741) of the CYP who were  
288 tested between 1<sup>st</sup> August 2020 and 31st December 2020.

289 The overall rate of PCR-confirmed infections was 179.4 (95% CI 176.9-182.0) per 1,000  
290 CYP-years. Young adults (aged 18-22 years) had the highest rates of PCR-confirmed  
291 infections and those aged 1-4 years the lowest (Appendix Table 4 & 5). Infants had the  
292 highest PCR-confirmed infection rates in preschool children, otherwise infection rates were  
293 positively correlated with age. Among the infants who tested positive 20.3% (56/276) were  
294 aged <3months and 38.8% (107/276) aged <6months. Overall, CYP from higher SEP groups  
295 and those with no history of chronic conditions had a higher risk of PCR-confirmed infection  
296 (Table 3). As we identified statistically significant interaction terms between age group and  
297 each of the other main risk factors, we conducted stratified analyses by age group (Table 5).  
298 These results showed that among infants and preschool children, PCR-confirmed infection  
299 rates were lower among higher SEP groups, whereas among CYP aged 12 and above,  
300 children from higher SEP groups were more likely to be infected. Infants with chronic  
301 conditions had higher infection rates than those without; the opposite was true for CYP aged  
302  $\geq 12$  years.

303 Additional analyses suggested that children aged <5 years with one older sibling had a  
304 reduced risk of a PCR confirmed infection compared to children with no older siblings (HR  
305 0.63 (95%CI: 0.49-0.81) and 0.86 (95%CI: 0.76-0.98) for infants and 1-4 year olds,  
306 respectively, Appendix Table 6). Further, in children aged 12-17 years, being  
307 overweight/obese increased the risk of a PCR-confirmed infection compared to being of  
308 normal BMI (HR: 1.07 (95%CI: 1.00-1.15), Appendix Table 6).



309  
310  
311

**Table 5 Time to PCR confirmed infection: hazard ratios (HR) by age group mutually adjusted for sex, socio-economic position and history of chronic conditions**

	Age <1 years		Age 1-4 years		Age 5-11 years		Age 12-17 years		Age 18-22 years	
Number of CYP in model	9661		49288		70245		76262		70212	
Number of PCR confirmed infections	276		1114		1286		2706		4338	
	AdjHR	95%CI	AdjHR	95%CI	AdjHR	95%CI	AdjHR	95%CI	AdjHR	95%CI
<b>SEX</b>										
Male	1	-	1	-	1	-	1	-	1	-
Female	1.16	0.94, 1.42	1.08	0.97, 1.21	1.11	1.03, 1.19	1.20	1.14, 1.26	0.95	0.91, 0.99
<b>SOCIO-ECONOMIC POSITION</b>										
High	0.70	0.49, 0.99	0.76	0.64, 0.92	0.86	0.75, 0.99	1.11	1.02, 1.20	1.52	1.43, 1.63
Middle	0.99	0.80, 1.24	0.99	0.88, 1.11	1.08	1.00, 1.17	1.13	1.07, 1.19	1.14	1.09, 1.19
Low	1	-	1	-	1	-	1	-	1	-
<b>CHRONIC CONDITIONS</b>										
None	1	-	1	-	1	-	1	-	1	-
One	1.03	0.56, 1.88	0.80	0.63, 1.02	0.96	0.82, 1.14	0.86	0.77, 0.97	0.78	0.71, 0.84
More than one	2.04	1.08, 3.82	0.71	0.39, 1.29	0.86	0.52, 1.44	0.80	0.57, 1.13	0.42	0.41, 0.73

312  
313

314 *COVID19-related-hospital admissions*


315 Between 1<sup>st</sup> February 2020 and 31 December 2020, 55,940 CYP in the cohort were admitted  
316 to hospital at least once, accounting for 81,312 admissions. Of these admissions, 346 (0.6%)  
317 in 318 CYP were identified as COVID-19-related admissions. 25 CYP were admitted more  
318 than once. The median time to re-admission was 5 (IQR 2-12) days. The median length of  
319 stay was 2 days (IQR 1-4 days). There were 110 admissions between February and July  
320 (31.8%) and 236 (68.2%) between August and December (Figure 3).

321 Of the 346 COVID-19-related admissions 203 (58.7%) had a U07.1/U07.2 recorded as  
322 primary diagnosis and 258 (74.6%) were temporally associated with a SARS-CoV-2 positive  
323 test with or without a primary or secondary U07.1/U07.2 diagnosis (Figure 4).

324 The overall COVID-19 related admission rate was 29.4/100,000 (95%CI 26.3-32.8) CYP  
325 years. Infants had the highest COVID-19 related admission rate across the age groups:  
326 120.6/100,000 (95%CI 92.2-157.9). CYP with more than one chronic condition type recorded  
327 had the highest admission rates across all age groups (Appendix table 7 & 8). Overall,  
328 12.0% ( $n=38$ ) of the 318 CYP admitted had at least one type of chronic condition, and 6.9%  
329 ( $n=22$ ) had multiple types of chronic conditions recorded; thus 88% of admitted CYP did not  
330 have an underlying chronic condition.

331 Of the CYP with chronic conditions who had a COVID-19 related admission,  
332 neurological/sensory conditions were the common condition type recorded among children  
333 aged<12 years, whereas among those aged 12-22 years the most common conditions were  
334 developmental/mental health conditions followed by  
335 metabolic/gastrointestinal/endocrine/genitourinary conditions.


336 Across all ages, presence of one or more chronic condition increased the risk of COVID-19-  
337 related admissions and CYP from lower SEP groups had the highest risk of COVID-19-  
338 related admission (Table 3). We identified statistically significant interaction terms between  
339 age group and each of the other main risk factors, and therefore conducted age-stratified  
340 analyses (Table 6). Having more than one chronic condition remained the strongest risk  
341 factor for COVID-19-related admission across all age groups. There was no statistically  
342 significant association between prematurity, number of older siblings, or BMI category and  
343 COVID-19 related hospital admission risk (Appendix Table 9).



344

345 **Figure 3** Monthly number of COVID-related hospital admissions (week 5-52, year 2020; 1<sup>st</sup>  
346 February 2020 to 31<sup>st</sup> December 2020)

347



348

349 **Figure 4** Number of COVID-related admissions temporally associated with PCR positive test  
350 up to 14 days before admission and by primary and secondary COVID19 diagnosis  
351 (U07.1/U07.2) Total admissions (n)= 346

352

353

354 **Table 6 Time-to-COVID related admissions: hazard ratios (HR) by age group mutually adjusted for sex, socio-economic position and**  
 355 **history of chronic conditions**

	Age <1 year		Age 1-4 years		Age 5-11 years		Age 12-17 years		Age 18-22 years	
Number of CYP in model	92,530		251,884		347,542		385,664		268,467	
N Admissions	53		51		55		49		110	
	AdjHR	95%CI	AdjHR	95%CI	AdjHR	95%CI	AdjHR	95%CI	AdjHR	95%CI
<b>SEX</b>										
Male	1	-	1	-	1	-	1	-	1	-
Female	0.81	0.51, 1.29	1.40	0.83, 2.36	0.96	0.54, 1.70	1.09	0.69, 1.72	1.47	0.99, 2.17
<b>Socio-economic position</b>										
High	0.47	0.18, 1.19	0.47	0.17, 1.34	0.90	0.34, 2.38	0.31	0.10, 1.01	0.62	0.26, 1.45
Middle	0.82	0.51, 1.32	0.68	0.40, 1.17	0.91	0.49, 1.66	1.02	0.64, 1.63	0.74	0.50, 1.09
Low	1	-	1	-	1	-	1	-	1	-
<b>CHRONIC CONDITIONS</b>										
None	1	-	1	-	1	-	1	-	1	-
One	1.37	0.34, 5.60	1.43	0.52, 3.98	3.30	1.40, 7.80	3.16	1.51, 6.61	3.75	2.34, 5.99
More than one	17.92	7.21, 44.55	12.87	5.12, 32.40	12.33	2.97, 51.17	20.93	9.03, 48.53	8.16	3.56, 18.75

356

357

358 *ICU admissions and PIMS-TS cases*

359 Thirteen (3.8%) of the 346 COVID-related admissions involved an ICU attendance,  
360 accounting for 1.2% of the 1,238 ICU admissions in CYP during the study period. Around  
361 half of these admissions were in CYP with a history of one or more types of chronic  
362 conditions. The median age of CYP admitted to ICU was 14 years (IQR 9-19 years) and the  
363 median length of stay at ICU was 6 days (IQR 2-7 days). Half of COVID-related ICU  
364 admissions were in boys.

365 We identified less than five admissions with a diagnosis suggestive of PIMS-TS and  
366 temporally associated with a positive PCR test (<28 days prior admission by definition), all in  
367 males with an age spanning from 9 to 14 years. The median length of stay at admission was  
368 10 days (IQR 6-14).

369 *Sensitivity analyses*

370 Among the 346 COVID related admissions, 199 (57.5%) were emergency admissions with a  
371 primary diagnosis of U07.1/U07.2. Using the more specific definition, the COVID-19 related  
372 hospital admission rates were 107.0 (95% CI 80.4-142.4), 13.4 (9.0-19.8), 8.0 (5.6 – 11.7),  
373 9.3 (6.3-13.6) and 27.7 (21.6-35.5) per 100,000 CYP years in age groups <1, 1-4, 5-11, 12-  
374 17 and 18-22 years respectively (Appendix Table 10 &11). This is 1.8 to 2 times higher than  
375 the more inclusive definition for CYP aged  $\geq 1$  year. Refitting the Cox proportional hazard  
376 models by age using the specific definition confirmed that presence of one or more chronic  
377 conditions remained the only significant risk factor for hospital admission (Appendix Tables  
378 12 & 13). The median length of stay remained 2 days (IQR 1-5).

379 **Discussion**

380 Over one fifth of CYP in Scotland had at least one SARS-CoV-2 PCR test during 2020, and  
381 1.5% had a PCR-confirmed infection. Testing rates increased with increasing age. PCR-  
382 confirmed infection rates were highest in 18–22-year-olds, followed by secondary school  
383 children and infants. CYP with chronic conditions were more likely to be tested, but CYP with  
384 chronic conditions of secondary school age or older were less likely to have a PCR  
385 confirmed infection. Whilst COVID-19 related hospital admissions were uncommon (less  
386 than 3 per 10,000 CYP admitted in 2020), infants and those with multiple types of chronic  
387 conditions recorded had the highest COVID-19 related-admission rates. Preschool children  
388 from lower SEP groups were more likely to have PCR-confirmed infection, and secondary  
389 school children and young adults from lower SEP groups less likely. Across all ages, SEP  
390 was significantly associated with COVID-related hospital admission. We identified no

391 statistically significant associations between prematurity, nor BMI and COVID-related  
392 admission risk; however the number of children admitted was small.

393 The well-established Scottish data linkage infrastructure allowed us to include data for all  
394 CYP born in Scotland since 1997, thereby minimising selection bias and loss to follow-up.  
395 We relied on linkage between hospital admission and public health surveillance data to  
396 define COVID-19-related admissions, allowing us to examine the robustness of our  
397 definitions in the linked data, rather than only relying on time difference between SARS-CoV-  
398 2 positive test and hospital admission alone. Importantly, by using a national birth cohort for  
399 this study, we could examine variations in population-based rates of SARS-CoV-2 testing,  
400 PCR confirmed infections and COVID-19-related hospital admissions across the full CYP  
401 age range, rather than only examining risk factors for ICU admission and death in  
402 hospitalised children. Using a population-wide study sample also minimises the risk of  
403 collider bias<sup>28</sup> which may risk validity in studies only including hospitalised patients.

404 Despite the use of a national birth cohort, we were unable to determine risk factors for rarer  
405 outcomes including COVID-19-related ICU admission and cases of PIMS-TS. Pooling results  
406 across multiple countries with data linkage capabilities allowing national CYP birth cohorts to  
407 be created, could provide reliable risk estimates for these more severe outcomes following  
408 SARS-CoV-2 infection in CYP.

409 Further, this study included data from the first year of the pandemic, when wildtype (until  
410 November 2020), followed by Alpha (dominant from December 2020) SARS-CoV-2 variants  
411 were circulating in Scotland. This study will need to be repeated to examine the impact of  
412 new circulating variants, including Delta and Omicron, and changing transmission dynamics  
413 as vaccination of adults appear to be concentrating virus circulation among younger age  
414 groups.<sup>29</sup> Recommendations to vaccinate high risk children aged 12 years and older against  
415 SARS-CoV-2 with two doses of Pfizer-BioNTech (BNT162b2; COMIRNATY) COVID vaccine  
416 was introduced in July 2021 in the UK; prior to this only children aged 12 and older with  
417 severe neurodisability, and 16-17 year olds with underlying conditions were recommended  
418 vaccination.<sup>30</sup> In August and September 2021, these recommendations changed to advise  
419 vaccination with one dose for all 16-17 olds (due to risk of myocarditis), and then all children  
420 aged 12 years and above respectively.<sup>31 32</sup> The US Food and Drug Administration approved  
421 the Pfizer-BioNTech vaccine for use in 5-11 year olds in late October 2021. Vaccination of  
422 children is likely to change risks of hospital admission, particularly among children with  
423 multiple chronic conditions. Whilst the benefits of vaccines may extend to non-health  
424 domains (e.g. school absences), further studies will need to examine whether the COVID-19  
425 vaccination programme has amended the admission risks reported in this study. However,

426 the results reported here provide a baseline during the first pandemic year against which  
427 more recent data can be compared.

428 We based our classification of chronic conditions on coded information in SMR-01 and SBR  
429 records; this may mean we have missed some conditions that are primarily managed in  
430 primary or community care settings. Our classification of socio-economic position was based  
431 on parental occupation derived from birth certificates, however, particularly among older  
432 CYP this may not reflect current socio-economic circumstances.

433 We highlight that infants have the highest admission risk among CYP, despite higher testing  
434 rates in older children and young adults. A previous systematic review (preprint) has  
435 indicated that infants are also at highest risk of requiring PICU admission once in hospital  
436 with COVID-19 disease.<sup>14</sup> However, admission rates in infancy related to SARS-CoV-2  
437 (1/1000 child-years) is lower than admission rates associated with confirmed influenza  
438 (2/1000 child-years)<sup>33</sup> or respiratory syncytial virus infections (22/1000-child years).<sup>34</sup> Future  
439 research should examine how COVID-19 vaccination programmes for pregnant women and  
440 older children, and removal of non-pharmaceutical interventions to control population mixing,  
441 affect infant SARS-CoV-2 admission rates.

442 We demonstrated that a history of chronic conditions, and particularly living with multiple  
443 different types of chronic conditions, was the most prominent risk factor for COVID-19  
444 related hospital admission rates among CYP, however the vast majority of admitted children  
445 had no chronic conditions recorded. Children with chronic conditions also experience higher  
446 hospital admission rates for other conditions and injuries.<sup>35</sup> CYP with chronic conditions were  
447 more likely to be tested than those without, however in older age groups CYP with chronic  
448 conditions were less likely to be positive. This may reflect lower threshold for testing among  
449 high-risk groups.

450 Preschool children from lower SEP groups (indicated by parental occupation recorded on the  
451 birth certificate) had higher risks of PCR-confirmed infection than children from higher SEP  
452 groups. This may be because younger children are spending more time in the home with  
453 their parents, and their risk of infection is therefore more strongly associated with their  
454 parents' occupation (and ability to work from home). In older CYP, we instead identified  
455 higher PCR-confirmed infection rates among higher SEP groups, despite lower testing rates.  
456 This may be due to CYP from lower SEP groups being less likely to attend post-16  
457 education, including university. Large outbreaks occurred in universities in Scotland in the  
458 autumn of 2020, which led to a surge in case numbers in 18-22 year olds.<sup>36</sup> Linkage  
459 between SARS-CoV-2 test results, hospital admission and education data are required to



460 confirm whether exposure in education settings can explain these differences in infection  
461 risk.

462 Low SEP at birth was also a risk factor for COVID-19-related admission in CYP in the overall  
463 model (incorporating all ages). This confirms previous reports which have indicated higher  
464 risk of severe outcomes in hospitalised adult COVID patients from more deprived areas,<sup>37</sup>  
465 and higher all-age hospital admission rates in areas with higher area deprivation scores.<sup>38 39</sup>  
466 Although we did not identify SEP as a significant risk factor for admission in age group  
467 specific models, COVID-19 related admission rates in children are much lower than in  
468 adults. Therefore, systematic differences in admission rates by SEP among specific age  
469 groups of CYP are harder to detect, even when using national data.

470 Our results showing that COVID-19 related admission rates in CYP peak in infancy indicates  
471 that further research and efforts to prevent COVID-19 admissions in children should include  
472 a focus on this age group. Pregnant women in Scotland are recommended to receive two  
473 doses of Pfizer/BioNTech COVID-19 vaccine.<sup>40</sup> As for pertussis<sup>41 42</sup> and influenza,<sup>43 44</sup>  
474 maternal vaccination during pregnancy could protect young babies from SARS-CoV-2  
475 infection, however no studies to date have examined this. Further, given that CYP with  
476 chronic conditions are more likely to be admitted to hospital admission with COVID-19  
477 disease than other CYP, studies monitoring the effectiveness of COVID-19 vaccines against  
478 severe outcomes in these high-risk groups are required to determine whether vaccination  
479 reduces the risk of admission.

480 We identified a peak in COVID-19-related hospital admissions in infants, and presence of  
481 chronic conditions as the strongest risk factor for hospital admissions in CYP, although the  
482 majority of admitted children did not have chronic conditions recorded. Further studies are  
483 urgently needed to examine whether maternal vaccine during pregnancy prevents COVID-19  
484 admissions in infants. These data also provide baseline risks of infection and hospital  
485 admission for risk-benefit assessments of childhood vaccination, particularly for preschool  
486 children.

487

488 **Ethics statement**

489 This study was approved by the University of Edinburgh School of Geosciences Ethics  
490 Committee (reference number 2020-401) and the Public Benefit and Privacy Panel for  
491 Health and Social Care (reference 1819-0049).

492 **Funding:**

493 UKRI-Medical Research Council

494 **Acknowledgements**

495 We are grateful to Professor Bianca De Stavola (UCL) for her advice on statistical modelling,  
496 and Diane Rennie from Public Health Scotland for her help with data access and disclosure  
497 checking. This work uses data provided by patients and collected by the NHS as part of their  
498 care and support

499 **Conflicts of interest**

500 None

501

## 502 References

- 503 1. Davies NG, Klepac P, Liu Y, et al. Age-dependent effects in the transmission and control  
504 of COVID-19 epidemics. *Nature Medicine* 2020;26(8):1205-11. doi: 10.1038/s41591-  
505 020-0962-9
- 506 2. European Centre for Disease Prevention and Control. COVID-19 in children and the role  
507 of school settings in transmission - first update. 2020  
508 [https://www.ecdc.europa.eu/sites/default/files/documents/COVID-19-in-children-and-](https://www.ecdc.europa.eu/sites/default/files/documents/COVID-19-in-children-and-the-role-of-school-settings-in-transmission-first-update_1.pdf)  
509 [the-role-of-school-settings-in-transmission-first-update\\_1.pdf](https://www.ecdc.europa.eu/sites/default/files/documents/COVID-19-in-children-and-the-role-of-school-settings-in-transmission-first-update_1.pdf) Accessed: 02/03/2021
- 510 3. Centre for Disease Control and Prevention. Coronavirus Disease 2019 in Children —  
511 United States, February 12–April 2, 2020. . *MMWR Morb Mortal Wkly Rep*  
512 2020;69:422–26. doi: <http://dx.doi.org/10.15585/mmwr.mm6914e4>
- 513 4. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus  
514 Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314  
515 Cases From the Chinese Center for Disease Control and Prevention. *JAMA*  
516 2020;323(13):1239-42. doi: 10.1001/jama.2020.2648
- 517 5. Tagarro A, Epalza C, Santos M, et al. Screening and Severity of Coronavirus Disease  
518 2019 (COVID-19) in Children in Madrid, Spain. *JAMA Pediatrics* 2021;175(3):316-17.  
519 doi: 10.1001/jamapediatrics.2020.1346
- 520 6. Office for National Statistics. Coronavirus (COVID-19) Infection Survey, UK: 3 December  
521 2021. 2021  
522 [https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditio-](https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/coronaviruscovid19infectionsurveypilot/3december2021)  
523 [nsanddiseases/bulletins/coronaviruscovid19infectionsurveypilot/3december2021](https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/coronaviruscovid19infectionsurveypilot/3december2021)  
524 Accessed: 16/12/2021
- 525 7. Swann OV, Holden KA, Turtle L, et al. Clinical characteristics of children and young  
526 people admitted to hospital with covid-19 in United Kingdom: prospective multicentre  
527 observational cohort study. *BMJ* 2020;370:m3249. doi: 10.1136/bmj.m3249
- 528 8. Göttinger F, Santiago-García B, Noguera-Julián A, et al. COVID-19 in children and  
529 adolescents in Europe: a multinational, multicentre cohort study. *The Lancet Child &*  
530 *Adolescent Health* 2020;4(9):653-61. doi: 10.1016/S2352-4642(20)30177-2
- 531 9. Irfan O, Muttalib F, Tang K, et al. Clinical characteristics, treatment and outcomes of  
532 paediatric COVID-19: a systematic review and meta-analysis. *Archives of Disease in*  
533 *Childhood* 2021;106(5):440-48. doi: 10.1136/archdischild-2020-321385
- 534 10. Toubiana J, Levy C, Allali S, et al. Association between SARS-CoV-2 infection and  
535 Kawasaki-like multisystem inflammatory syndrome: a retrospective matched case–  
536 control study, Paris, France, April to May 2020. *Eurosurveillance*  
537 2020;25(48):2001813. doi: [https://doi.org/10.2807/1560-](https://doi.org/10.2807/1560-7917.ES.2020.25.48.2001813)  
538 [7917.ES.2020.25.48.2001813](https://doi.org/10.2807/1560-7917.ES.2020.25.48.2001813)
- 539 11. Belot A, Antona D, Renolleau S, et al. SARS-CoV-2-related paediatric inflammatory  
540 multisystem syndrome, an epidemiological study, France, 1 March to 17 May 2020.  
541 *Eurosurveillance* 2020;25(22):2001010. doi: [https://doi.org/10.2807/1560-](https://doi.org/10.2807/1560-7917.ES.2020.25.22.2001010)  
542 [7917.ES.2020.25.22.2001010](https://doi.org/10.2807/1560-7917.ES.2020.25.22.2001010)
- 543 12. Whittaker E, Bamford A, Kenny J, et al. Clinical Characteristics of 58 Children With a  
544 Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-  
545 CoV-2. *JAMA* 2020;324(3):259-69. doi: 10.1001/jama.2020.10369
- 546 13. Flood J, Shingleton J, Bennett E, et al. Paediatric multisystem inflammatory syndrome  
547 temporally associated with SARS-CoV-2 (PIMS-TS): Prospective, national  
548 surveillance, United Kingdom and Ireland, 2020. *The Lancet Regional Health –*  
549 *Europe* 2021;3 doi: 10.1016/j.lanep.2021.100075
- 550 14. Harwood R, Yan H, Da Camara NT, et al. Which children and young people are at higher  
551 risk of severe disease and death after SARS-CoV-2 infection: a systematic review  
552 and individual patient meta-analysis. *medRxiv* 2021:2021.06.30.21259763. doi:  
553 10.1101/2021.06.30.21259763

- 554 15. Ward JL, Harwood R, Smith C, et al. Risk factors for intensive care admission and death  
555 amongst children and young people admitted to hospital with COVID-19 and PIMS-  
556 TS in England during the first pandemic year. *medRxiv* 2021:2021.07.01.21259785.  
557 doi: 10.1101/2021.07.01.21259785
- 558 16. Witberg G, Barda N, Hoss S, et al. Myocarditis after Covid-19 Vaccination in a Large  
559 Health Care Organization. *New England Journal of Medicine* 2021;385(23):2132-39.  
560 doi: 10.1056/NEJMoa2110737
- 561 17. Simone A, Herald J, Chen A, et al. Acute Myocarditis Following COVID-19 mRNA  
562 Vaccination in Adults Aged 18 Years or Older. *JAMA Internal Medicine*  
563 2021;181(12):1668-70. doi: 10.1001/jamainternmed.2021.5511
- 564 18. Shi T, Pan J, Katikireddi SV, et al. Risk of COVID-19 hospital admission among children  
565 aged 5-17 years with asthma in Scotland: a national incident cohort study. *The*  
566 *Lancet Respiratory Medicine* doi: 10.1016/S2213-2600(21)00491-4
- 567 19. Favarato G, Clemens T, Cunningham S, et al. Air Pollution, housing and respiratory tract  
568 Infections in Children: Natlonal birth Cohort study (PICNIC): study protocol. *BMJ*  
569 *Open* 2021;11(5):e048038. doi: 10.1136/bmjopen-2020-048038
- 570 20. Hardelid P, Verfuenden M, McMenamin J, et al. The contribution of child, family and  
571 health service factors to respiratory syncytial virus (RSV) hospital admissions in the  
572 first 3 years of life: birth cohort study in Scotland, 2009 to 2015. *Eurosurveillance*  
573 2019;24(1):1800046. doi: [https://doi.org/10.2807/1560-](https://doi.org/10.2807/1560-7917.ES.2019.24.1.1800046)  
574 [7917.ES.2019.24.1.1800046](https://doi.org/10.2807/1560-7917.ES.2019.24.1.1800046)
- 575 21. Fenton L, Gribben C, Caldwell D, et al. Risk of hospital admission with covid-19 among  
576 teachers compared with healthcare workers and other adults of working age in  
577 Scotland, March 2020 to July 2021: population based case-control study. *BMJ*  
578 2021;374:n2060. doi: 10.1136/bmj.n2060
- 579 22. Osborn DPJ, Favarato G, Lamb D, et al. Readmission after discharge from acute mental  
580 healthcare among 231 988 people in England: cohort study exploring predictors of  
581 readmission including availability of acute day units in local areas. *BJPsych Open*  
582 2021;7(4):e136. doi: 10.1192/bjo.2021.961
- 583 23. Office for National Statistics. The National Statistics Socio-economic classification (NS-  
584 SEC); 2010  
585 [https://www.ons.gov.uk/methodology/classificationsandstandards/otherclassifications](https://www.ons.gov.uk/methodology/classificationsandstandards/otherclassifications/thenationalstatistics socioeconomicclassificationnssecrebasedonsoc2010)  
586 [/thenationalstatistics socioeconomicclassificationnssecrebasedonsoc2010](https://www.ons.gov.uk/methodology/classificationsandstandards/otherclassifications/thenationalstatistics socioeconomicclassificationnssecrebasedonsoc2010)
- 587 24. Hardelid P, Davey J, Dattani N, et al. Child deaths due to injury in the four UK countries:  
588 a time trends study from 1980 to 2010. *PLoS One* 2013;8(7):e68323. doi:  
589 10.1371/journal.pone.0068323
- 590 25. Cole TJ, Freeman JV, Preece MA. British 1990 growth reference centiles for weight,  
591 height, body mass index and head circumference fitted by maximum penalized  
592 likelihood. *Stat Med* 1998;17(4):407-29.
- 593 26. SCHOENFELD D. Partial residuals for the proportional hazards regression model.  
594 *Biometrika* 1982;69(1):239-41. doi: 10.1093/biomet/69.1.239
- 595 27. Public Health Scotland. Scottish Clinical Coding Standards – ICD-10. 2020  
596 [https://www.isdscotland.org/Products-and-Services/Terminology-Services/Clinical-](https://www.isdscotland.org/Products-and-Services/Terminology-Services/Clinical-Coding-Guidelines/Docs/SCCS-24-April-2020.pdf)  
597 [Coding-Guidelines/Docs/SCCS-24-April-2020.pdf](https://www.isdscotland.org/Products-and-Services/Terminology-Services/Clinical-Coding-Guidelines/Docs/SCCS-24-April-2020.pdf) Accessed:
- 598 28. Griffith GJ, Morris TT, Tudball MJ, et al. Collider bias undermines our understanding of  
599 COVID-19 disease risk and severity. *Nature Communications* 2020;11(1):5749. doi:  
600 10.1038/s41467-020-19478-2
- 601 29. Public Health Scotland. COVID-19 Daily Dashboard; 2021  
602 [https://public.tableau.com/app/profile/phs.covid.19/viz/COVID-](https://public.tableau.com/app/profile/phs.covid.19/viz/COVID-19DailyDashboard_15960160643010/Overview)  
603 [19DailyDashboard\\_15960160643010/Overview](https://public.tableau.com/app/profile/phs.covid.19/viz/COVID-19DailyDashboard_15960160643010/Overview)
- 604 30. Joint Committee of Vaccination and Immunisation. JCVI statement on COVID-19  
605 vaccination of children and young people aged 12 to 17 years: 15 July 2021; 2021  
606 [https://www.gov.uk/government/publications/covid-19-vaccination-of-children-and-](https://www.gov.uk/government/publications/covid-19-vaccination-of-children-and-young-people-aged-12-to-17-years-jcvi-statement/jcvi-statement-on-covid-19-vaccination-of-children-and-young-people-aged-12-to-17-years-15-july-2021)  
607 [young-people-aged-12-to-17-years-jcvi-statement/jcvi-statement-on-covid-19-](https://www.gov.uk/government/publications/covid-19-vaccination-of-children-and-young-people-aged-12-to-17-years-jcvi-statement/jcvi-statement-on-covid-19-vaccination-of-children-and-young-people-aged-12-to-17-years-15-july-2021)  
608 [vaccination-of-children-and-young-people-aged-12-to-17-years-15-july-2021](https://www.gov.uk/government/publications/covid-19-vaccination-of-children-and-young-people-aged-12-to-17-years-jcvi-statement/jcvi-statement-on-covid-19-vaccination-of-children-and-young-people-aged-12-to-17-years-15-july-2021)

- 609 31. Joint Committee of Vaccination and Immunisation. JCVI statement on COVID-19  
610 vaccination of children and young people aged 12 to 17 years: 4 August 2021; 2021  
611 [https://www.gov.uk/government/publications/jcvi-statement-august-2021-covid-19-](https://www.gov.uk/government/publications/jcvi-statement-august-2021-covid-19-vaccination-of-children-and-young-people-aged-12-to-17-years/jcvi-statement-on-covid-19-vaccination-of-children-and-young-people-aged-12-to-17-years-4-august-2021)  
612 [vaccination-of-children-and-young-people-aged-12-to-17-years/jcvi-statement-on-](https://www.gov.uk/government/publications/jcvi-statement-august-2021-covid-19-vaccination-of-children-and-young-people-aged-12-to-17-years/jcvi-statement-on-covid-19-vaccination-of-children-and-young-people-aged-12-to-17-years-4-august-2021)  
613 [covid-19-vaccination-of-children-and-young-people-aged-12-to-17-years-4-august-](https://www.gov.uk/government/publications/jcvi-statement-august-2021-covid-19-vaccination-of-children-and-young-people-aged-12-to-17-years/jcvi-statement-on-covid-19-vaccination-of-children-and-young-people-aged-12-to-17-years-4-august-2021)  
614 [2021](https://www.gov.uk/government/publications/jcvi-statement-august-2021-covid-19-vaccination-of-children-and-young-people-aged-12-to-17-years/jcvi-statement-on-covid-19-vaccination-of-children-and-young-people-aged-12-to-17-years-4-august-2021)
- 615 32. Joint Committee of Vaccination and Immunisation. JCVI statement on COVID-19  
616 vaccination of children aged 12 to 15 years: 3 September 2021; 2021  
617 [https://www.gov.uk/government/publications/jcvi-statement-september-2021-covid-](https://www.gov.uk/government/publications/jcvi-statement-september-2021-covid-19-vaccination-of-children-aged-12-to-15-years/jcvi-statement-on-covid-19-vaccination-of-children-aged-12-to-15-years-3-september-2021)  
618 [19-vaccination-of-children-aged-12-to-15-years/jcvi-statement-on-covid-19-](https://www.gov.uk/government/publications/jcvi-statement-september-2021-covid-19-vaccination-of-children-aged-12-to-15-years/jcvi-statement-on-covid-19-vaccination-of-children-aged-12-to-15-years-3-september-2021)  
619 [vaccination-of-children-aged-12-to-15-years-3-september-2021](https://www.gov.uk/government/publications/jcvi-statement-september-2021-covid-19-vaccination-of-children-aged-12-to-15-years/jcvi-statement-on-covid-19-vaccination-of-children-aged-12-to-15-years-3-september-2021)
- 620 33. Hardelid P, Verfuenden M, McMenamin J, et al. Risk factors for admission to hospital  
621 with laboratory-confirmed influenza in young children: birth cohort study. *Eur Resp J*  
622 2017;50(3) doi: 10.1183/13993003.00489-2017
- 623 34. Hardelid P, Verfuenden M, McMenamin J, et al. The contribution of child, family and  
624 health service factors to respiratory syncytial virus (RSV) hospital admissions in the  
625 first 3 years of life: birth cohort study in Scotland, 2009 to 2015. *Euro Surveill*  
626 2019;24(1) doi: 10.2807/1560-7917.ES.2019.24.1.1800046
- 627 35. Wijlaars LH, P; Guttman, A; Gilbert, R; . Emergency admissions and long-term  
628 conditions during transition from paediatric to adult care: a cross-sectional study  
629 using Hospital Episode Statistics data. Under review in *BMJ Open*. 2018 Accessed:
- 630 36. Public Health Scotland. COVID-19 in Scotland Daily Dashboard: Trends and  
631 demographics; 2021 [https://public.tableau.com/app/profile/phs.covid.19/viz/COVID-](https://public.tableau.com/app/profile/phs.covid.19/viz/COVID-19DailyDashboard_15960160643010/Overview)  
632 [19DailyDashboard\\_15960160643010/Overview](https://public.tableau.com/app/profile/phs.covid.19/viz/COVID-19DailyDashboard_15960160643010/Overview)
- 633 37. Lone NI, McPeake J, Stewart NI, et al. Influence of socioeconomic deprivation on  
634 interventions and outcomes for patients admitted with COVID-19 to critical care units  
635 in Scotland: A national cohort study. *The Lancet Regional Health – Europe* 2021;1  
636 doi: 10.1016/j.lanepe.2020.100005
- 637 38. The Scottish Parliament. Health Inequality and COVID-19 in Scotland. 2021  
638 [https://digitalpublications.parliament.scot/ResearchBriefings/Report/2021/3/23/ee202](https://digitalpublications.parliament.scot/ResearchBriefings/Report/2021/3/23/ee202c60-93ad-4a27-a6e7-67613856ba24)  
639 [c60-93ad-4a27-a6e7-67613856ba24](https://digitalpublications.parliament.scot/ResearchBriefings/Report/2021/3/23/ee202c60-93ad-4a27-a6e7-67613856ba24) Accessed: 27/10/2021
- 640 39. Public Health England. Disparities in the risk and outcomes of COVID-19. 2020  
641 [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachm](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/908434/Disparities_in_the_risk_and_outcomes_of_COVID_August_2020_update.pdf)  
642 [ent\\_data/file/908434/Disparities in the risk and outcomes of COVID August 202](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/908434/Disparities_in_the_risk_and_outcomes_of_COVID_August_2020_update.pdf)  
643 [0\\_update.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/908434/Disparities_in_the_risk_and_outcomes_of_COVID_August_2020_update.pdf) Accessed: 27/10/2021
- 644 40. UK Health Security Agency. Green Book Chapter 14a: COVID-19 2021.
- 645 41. Dabrera G, Amirthalingam G, Andrews N, et al. A Case-Control Study to Estimate the  
646 Effectiveness of Maternal Pertussis Vaccination in Protecting Newborn Infants in  
647 England and Wales, 2012–2013. *Clinical Infectious Diseases* 2014;60(3):333-37. doi:  
648 10.1093/cid/ciu821
- 649 42. Sandmann F, Jit M, Andrews N, et al. Infant Hospitalizations and Fatalities Averted by  
650 the Maternal Pertussis Vaccination Program in England, 2012–2017: Post-  
651 implementation Economic Evaluation. *Clinical Infectious Diseases* 2020;71(8):1984-  
652 87. doi: 10.1093/cid/ciaa165
- 653 43. Benowitz I, Esposito DB, Gracey KD, et al. Influenza Vaccine Given to Pregnant Women  
654 Reduces Hospitalization Due to Influenza in Their Infants. *Clinical Infectious*  
655 *Diseases* 2010;51(12):1355-61. doi: 10.1086/657309
- 656 44. Mølgaard-Nielsen D, Fischer TK, Krause TG, et al. Effectiveness of maternal  
657 immunization with trivalent inactivated influenza vaccine in pregnant women and their  
658 infants. *Journal of Internal Medicine* 2019;286(4):469-80. doi:  
659 <https://doi.org/10.1111/joim.12947>

660

